Business
Medacta Group SA: Medacta Group reports continued significant above-market revenue growth of 18.5% in constant currency in 2025
Medacta Group SA: Medacta Group reports continued significant above-market revenue growth of 18.5% in constant currency in
About this update from Medacta Group Sa
Medacta Group SA / Key word(s): Preliminary Results Medacta Group SA: Medacta Group reports continued significant above-market revenue growth of 18.5% in constant currency in 2025 03-Feb-2026 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Media Release – Ad-hoc announcement pursuant to Art. 53 LR Medacta Group reports continued significant above-market revenue growth of 18.5% in constant currency in 20251 FY 2025 revenue accelerated to Euro 683.8 million, up 18.5% in c.c.1 or 15.8% in Euro Substantial revenue growth across all geographic marketsContinuous outstanding performance in all business lines due to its differentiating innovations258 new jobs created to foster further growth CASTEL SAN PIETRO, 3 February 2026 – Medacta Group SA (“Medacta”, SIX:MOVE) today announces its full year 2025 preliminary unaudited revenue. Francesco Siccardi, CEO of Medacta, commented: “We are very pleased with our continued outstanding growth performance, across all geographic markets and business lines against strong prior year comparables. Our dedication to improve patient outcomes and patient satisfaction drives our strong focus on differentiating innovations for minimally invasive techniques and personalized solutions as well as on surgeon-specific structured medical education. These key pillars, coupled with the constant expansion of our salesforce, are at the base of our successful expansion strategy. I am proud of the entire Medacta team in delivering such outstanding results.” In 2025, Medacta recorded Group revenue of Euro 683.8 million, an increase of 18.5% in constant currency and an increase of 15.8% in Euro. The acquisition of Parcus Medical in March 2025, the integration of which has been concluded, contributed approximately 1.5% to Group revenue. Medacta reported another year of outstanding growth in all geographic markets and continued superior growth across all business lines. This was achieved by the constant launch of our differentiating innovations across all business lines, our continued efforts in medical education and the attraction of new surgeons supported by our expanded sa...